{"id":"aecaa924-c555-587f-af82-4d8b4dcfb8b5","stable_key":"f992b796-377d-53bf-a39b-7e5d41dbe194:b5-clin-antagonist-variable-symptoms","predicate":"elicits-variable","statement":"In the four-man normal-diet experiment, the intermediate-antagonist subject developed gastrointestinal and neurological symptoms, while the highest-exposure subject had mainly a transient tremor; the control and lowest-exposure subject remained relatively well.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"1c27d7bc-83b8-5d92-94bd-bd2b99267dbe","mechanism_event_label":"Blocking vitamin use experimentally produced variable illness despite a normal diet.","subject":{"id":"e3aec528-bdfb-54a8-9b32-53fd3f1b9ff9","slug":"omega-methyl-pantothenate","display_name":"Omega-methyl pantothenic acid","entity_type_key":"small_molecule"},"object":{"id":"5d51faa4-fc18-506d-a2a3-7cc50b00fa2a","slug":"pantothenate-depletion-clinical-symptoms","display_name":"Clinical symptoms during pantothenate depletion","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"1c27d7bc-83b8-5d92-94bd-bd2b99267dbe","stable_key":"f992b796-377d-53bf-a39b-7e5d41dbe194:b5-clin-antagonist-variable-symptoms-event","event_type":"observed_intervention","label":"Blocking vitamin use experimentally produced variable illness despite a normal diet.","description":"In the four-man normal-diet experiment, the intermediate-antagonist subject developed gastrointestinal and neurological symptoms, while the highest-exposure subject had mainly a transient tremor; the control and lowest-exposure subject remained relatively well.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"7bc62072-9517-5563-a3b8-8c5ab64a464b","slug":"pantothenate","display_name":"Pantothenate (vitamin B5)","entity_type_key":"small_molecule"},"role":"vitamin antagonized experimentally","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"e3aec528-bdfb-54a8-9b32-53fd3f1b9ff9","slug":"omega-methyl-pantothenate","display_name":"Omega-methyl pantothenic acid","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"5d51faa4-fc18-506d-a2a3-7cc50b00fa2a","slug":"pantothenate-depletion-clinical-symptoms","display_name":"Clinical symptoms during pantothenate depletion","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"cross_nutrient","value_text":"false","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_location","value_text":"Primary PDF pp.1421–1425, especially Results and Summary.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Historical four-man controlled antagonist experiment on a balanced 3200 kcal diet","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"One control; three men received escalating antagonist regimens, up to 2–4 g/day in the highest-exposure subject; pantothenic acid 4 g/day was later given after antagonist withdrawal.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Pharmacological antagonist exposure with an otherwise normal diet, not dietary B5 deprivation. Very small sample and concurrent antagonist withdrawal prevent isolating a pure vitamin-rescue effect. The interindividual pattern is not a monotonic dose-response or a direct assay of a specific PANK isoform.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Pantothenic acid (vitamin B5) research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"pantothenate","display_name":"Pantothenate (vitamin B5)","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Blocking vitamin use experimentally produced variable illness despite a normal diet.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[b5-clin-hodges1959] Human pantothenic acid deficiency produced by omega-methyl pantothenic acid. (1959). https://pubmed.ncbi.nlm.nih.gov/13673099/ DOI: 10.1172/jci103918","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Whole-person clinical symptoms and functional tests","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"d84df587-bad9-5f6c-a394-5fd9ddad5b50","evidence_kind":"source_excerpt","locator":"Lines 1201-1213","start_line":1201,"end_line":1213,"excerpt":"### b5-clin-antagonist-variable-symptoms\nIn the four-man normal-diet experiment, the intermediate-antagonist subject developed gastrointestinal and neurological symptoms, while the highest-exposure subject had mainly a transient tremor; the control and lowest-exposure subject remained relatively well.\nCondition category: normal\nnutrient_topic: Pantothenic acid (vitamin B5) research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Blocking vitamin use experimentally produced variable illness despite a normal diet.\norganism: Homo sapiens\ntissue_or_cell_type: Whole-person clinical symptoms and functional tests\nexperimental_model: Historical four-man controlled antagonist experiment on a balanced 3200 kcal diet\nlimitations: Pharmacological antagonist exposure with an otherwise normal diet, not dietary B5 deprivation. Very small sample and concurrent antagonist withdrawal prevent isolating a pure vitamin-rescue effect. The interindividual pattern is not a monotonic dose-response or a direct assay of a specific PANK isoform.\nexposure: One control; three men received escalating antagonist regimens, up to 2–4 g/day in the highest-exposure subject; pantothenic acid 4 g/day was later given after antagonist withdrawal.\ncross_nutrient: false\nevidence_location: Primary PDF pp.1421–1425, especially Results and Summary.\n[b5-clin-hodges1959] Human pantothenic acid deficiency produced by omega-methyl pantothenic acid. (1959). https://pubmed.ncbi.nlm.nih.gov/13673099/ DOI: 10.1172/jci103918","model_system":"Historical four-man controlled antagonist experiment on a balanced 3200 kcal diet","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [b5-clin-hodges1959] Human pantothenic acid deficiency produced by omega-methyl pantothenic acid. (1959). https://pubmed.ncbi.nlm.nih.gov/13673099/ DOI: 10.1172/jci103918","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"0716b500-dd0b-5425-b9d0-d88bc9c09e86","stable_key":"import-f992b796-377d-53bf-a39b-7e5d41dbe194","title":"Pantothenic acid (vitamin B5): coenzyme A, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"b5a49f5a2373ca6064c9a4e014e052dad2f6f199a82bb09b26b82b831c36110b","revision_id":"78f3e793-f084-5ee2-8703-b661c4b650bf","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}